Value Health Sols. Inc. v. Pharm. Research Assocs.

2020 NCBC 41
North Carolina Business Court·Decided May 22, 2020·No. 18-CVS-12318·Published·Cited by 1 cases

Opinion

Value Health Sols., Inc. v. Pharm. Research Assocs., 2020 NCBC 41.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION

COUNTY OF WAKE 18-CV-12318

VALUE HEALTH SOLUTIONS INC. and NAGARAJAN PARTHASARATHY,

Plaintiffs,

v. ORDER AND OPINION ON DEFENDANTS’ MOTION TO

DISMISS AMENDED COMPLAINT PHARMACEUTICAL RESEARCH ASSOCIATES, INC. and PRA HEALTH SCIENCES, INC.,

Defendants.

THIS MATTER comes before the Court on Defendants Pharmaceutical Research Associates, Inc. (“PRA, Inc.”) and PRA Health Sciences, Inc.’s (“PRA Health”; collectively Defendants will be referred to herein as “PRA,” in the singular, except as otherwise required) Motion to Dismiss Plaintiffs’ Amended Complaint. (“Motion,” ECF No. 77.)

THE COURT, having considered the Motion, the briefs submitted in support of and in opposition to the Motion, the arguments of counsel at the hearing on the Motion, the applicable law, and other appropriate matters of record, CONCLUDES that the Motion should be GRANTED, in part, and DENIED, in part, for the reasons set forth below.

Mainsail Lawyers, by David Glen Guidry and Joseph Kellam Warren, for Plaintiffs Value Health Solutions Inc. and Nagarajan Parthasarathy.

Kilpatrick Townsend & Stockton LLP, by Randy Avram, John Moye, and Joe P. Reynolds, for Defendants Pharmaceutical Research Associates, Inc. and PRA Health Sciences, Inc.

McGuire, Judge.

I. FACTUAL AND PROCEDURAL BACKGROUND 1. The Court does not make findings of fact on motions to dismiss under Rule 12(b)(6), but only recites those facts included in the complaint that are relevant to the Court’s determination of the Motion. See, e.g., Concrete Serv. Corp. v. Inv’rs Grp., Inc., 79 N.C. App. 678, 681, 340 S.E.2d 755, 758 (1986). The facts relevant to the determination of the Motion are drawn from the Amended Complaint. (“Amended Complaint,” ECF No. 60.1.)

2. PRA is a “‘contract research organization’ or CRO, in the business of providing product development and data solution services primarily to drug companies.” (ECF No. 60.1, at ¶ 1.) PRA conducts clinical trials for pharmaceutical and biotech companies.

3. Plaintiff Value Health Solutions Inc. (“VHS”) is a developer of clinical trial management software that CROs use to manage clinical trials. Plaintiff Nagarajan Parthasarathy (“Parthasarathy”; collectively VHS and Parthasarathy are “Plaintiffs”) is the founder of VHS. VHS developed a set of clinical trial management software solutions called ClinTrial Max, Cloud Max, and Info Max (collectively, the “Software Solutions”). The Software Solutions were cloud-based programs designed to help drug companies (or CROs on behalf of drug companies) more efficiently manage the clinical trial process used to develop new drugs. (Id. at ¶ 18.)

4. In April 2014, PRA contacted Parthasarathy to express interest in acquiring the Software Solutions. In response, Parthasarathy and VHS provided a day-long demonstration of the software to PRA’s IT leadership team consisting of Chuck Piccirillo (“Piccirillo”), a senior VP in development, and Mike Irene, a PRA manager with extensive experience with clinical trial software. (Id. at ¶ 22.) Plaintiffs and PRA then engaged in a year-long period of due diligence and negotiation aimed at PRA’s acquisition of the Software Solutions. (Id. at ¶ 24.) VHS discussed licensing the Software Solutions to PRA in exchange for a recurring license payment, rather than selling the Software Solutions for a lump sum amount. (Id. at ¶ 26.) However, Plaintiffs allege on information and belief that PRA was not interested in licensing the Software Solutions from VHS because: (1) PRA wished to eliminate VHS as a competitor in the marketplace; and (2) prevent VHS from directly licensing the Software Solutions to drug companies or other CROs. (Id. at ¶ 27.)

5. Between April and October 2014, as part of the due diligence process, VHS provided PRA with full access to the software code and PRA performed testing and analysis to understand the functionality of VHS’s Software Solutions from both a technology and business operations perspective. (Id. at ¶¶ 28–29.) This included a gap analysis by which PRA learned the capabilities of the Software Solutions and identified the functions that PRA wanted to further develop after acquiring the software. (Id.)

6. On October 15, 2014, PRA Health’s Executive Vice President and Chief Financial Officer, Linda Baddour, sent Parthasarathy a Letter of Intent (“LOI”).

(ECF No. 5, at Ex. A.) 1 The LOI outlined PRA’s proposal for the acquisition of the Software Solutions as follows:

a. A one-time, up-front payment between $1 million and $3 million;

b. Future fixed payments of $333,000 each upon completion of three separate “Integration Milestones,”

described as (i) “Integrated Salesforce Environments,”

(ii) “Key Product Enhancements,” and (iii) “CTMS Studies Migrated to ClinTrial Max”; and

c. Future variable payments associated with “Performance Milestones” associated with “licenses for VHS” Software Solutions as follows:

i. a payment of $2.5 million for reaching $25 million in annual sales within two years of closing;

ii. a payment of $5 million for reaching $50 million in annual sales within three years of closing;

iii. a payment of $7.5 million for reaching $75 million in annual sales within four years of the closing; and

iv. a one percent (1%) annual royalty on sales for an additional four years after the $75 million sales amount is reached.

(ECF No. 60.1, at ¶ 32.)

7. Between October 2014 and May 2015, PRA was, again, given unfettered access to test and analyze the Software Solutions and had ready access to Parthasarathy and other VHS programmers to address questions about the Software Solutions. PRA had the opportunity to verify all information provided by VHS and

1 The copy of the LOI, attached to the original Complaint, is not signed by VHS, and Plaintiffs do not allege that Plaintiffs agreed to the LOI.

Parthasarathy regarding the Software Solutions. PRA also had the opportunity to analyze whether VHS’s Software Solutions had the ability to handle the scale and scope of PRA’s intended use for the software. (Id. at ¶¶ 36–39.)

8. Effective May 21, 2015, PRA, VHS, and Parthasarathy entered into an Asset Purchase Agreement (“APA”) for the purchase of the Software Solutions. (Id. at ¶ 40; ECF No. 5, at Ex. B.) Under the APA, PRA agreed to purchase the Software Solutions in exchange for a fixed payment at closing, and fixed and variable milestone payments to be made after closing, as follows:

Fixed payment at closing:

(a) Shares of PRA stock valued at $1,957,000.00 (see APA, §2.5(b)(i)), plus a payment of $500,000, at closing (see APA, § 2.5(b)(ii));

Fixed payments for software milestones:

(b) Shares of PRA stock valued at $333,000 for each of the agreed-upon “Milestones”:

(i) “integration of the Parties’ Salesforce environments,” as set forth on Schedule 2.6(a)(i) of the APA, within 18 months of closing ([see] APA, § 2.6(a)(i));

(ii) “completion of the key product enhancements” as set forth on Schedule 2.6(a)(ii) of the APA (see APA, §2.6(a)(ii))

within 18 months of closing;

(iii) “completion of the migration of the clinical trial management systems studies” of PRA “into ClinTrial Max” as set forth on Schedule 2.6(a)(iii) of the APA (see APA, § 2.6(a)(iii));

Variable payments for sales milestones:

(c) Payment of $2.5 million for reaching $25 million in External Sales[ ] within 2 years of closing (see APA, §2.6(a)(iv));

(d) Payment of $5 million for reaching $50 million in External Sales within 3 years of closing (see APA, §2.6(a)(v));

(e) Payment of $7.5 million for reaching $75 million in External Sales within 4 years of closing (see APA, §2.6(a)(vi)); and

(f) Payment of an annual royalty equal to one percent (1%) of the annual External Sales for an additional four years after reaching $75 million in External Sales (see APA, §2.6(a)(vii)).

(ECF No. 60.1, at ¶ 42.)

Free access — add to your briefcase to read the full text and ask questions with AI

Value Health Sols. Inc. v. Pharm. Research Assocs., 2020 NCBC 41 (N.C. Super. Ct. 2020).

2020 NCBC 41 (Value Health Sols. Inc. v. Pharm. Research Assocs.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related